Protective effect of cryotherapy against oral mucositis among allogeneic hematopoietic stem cell transplant recipients using melphalan-based conditioning

Purpose Oral cryotherapy is an effective method to prevent oral mucositis (OM) induced by chemotherapeutic agents, such as melphalan (Mel). However, there is limited data about cryotherapy in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients; thus, the current study aimed to...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2023-09, Vol.31 (9), p.521, Article 521
Main Authors: Oku, Saori, Futatsuki, Toshiko, Imamura, Yoshiko, Hikita, Haruna, Inada, Akemi, Mizutani, Shinsuke, Mori, Yasuo, Kashiwazaki, Haruhiko
Format: Article
Language:English
Subjects:
Cancer
Caspofungin
Chemotherapy
Comparative analysis
Cryotherapy
Disease prevention
Graft versus host disease
Hematopoietic stem cells
Medicine
Medicine & Public Health
Methotrexate
Mucositis
Nursing
Nursing Research
Oncology
Pain Medicine
Palifermin
Rehabilitation Medicine
Stem cell transplantation
Stem cells
Stomatitis
Transplantation
Transplants & implants
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Oral cryotherapy is an effective method to prevent oral mucositis (OM) induced by chemotherapeutic agents, such as melphalan (Mel). However, there is limited data about cryotherapy in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients; thus, the current study aimed to examine the efficacy of cryotherapy among allo-HSCT recipients treated with Mel-containing regimens. Methods Medical records of 78 consecutive allo-HSCT recipients were retrospectively analyzed. Baseline characteristics and clinical courses between the patients who received cryotherapy (cryotherapy group, n  = 42) and those who did not (control group, n  = 36) were compared, especially focusing on methotrexate (MTX) use as a part of graft-versus-host disease (GVHD) prophylaxis. Results Binary logistic regression analysis revealed that a higher dose of Mel (OR, 3.82; 95%CI, 1.085–13.46; P  = 0.037) or MTX use (OR, 7.61; 95% CI, 2.41–23.97; P  
ISSN:0941-4355
1433-7339
1433-7339
DOI:10.1007/s00520-023-07989-9